BC Extra | Sep 4, 2019
Preclinical News

Preclinical Quick Takes: NIH's clinical trial practices in preclinical studies, plus Kancera and optimized base editors

NIH to fund preclinical studies implementing clinical practices for stroke  NIH plans to fund a preclinical trial platform that uses clinical research practices to study therapies for stroke. NIH's NINDS will invest $4 million over...
BC Week In Review | Mar 2, 2018
Clinical News

Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers showing that lymphoma, inflammation and cardiovascular disease candidate KAND567 (AZD8797) was well tolerated. The double-blind, placebo-controlled trial evaluated single doses of...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Chemokine CX3C motif receptor 1 (CX3CR1)

Inflammation INDICATION: Shock / trauma Mouse studies suggest inhibiting CX3CR1 could help treat the chronic phase of traumatic brain injury (TBI). In a mouse model of chronic-phase TBI, CX3CR1 knockout decreased lesion size, hippocampal damage...
BC Week In Review | Apr 25, 2016
Clinical News

Anti-CX3CR1 Nanobody: Phase I started

Boehringer began a Phase I trial to evaluate single ascending doses of IV anti-CX3CR1 Nanobody. The start triggered a EUR8 million ($9 million) milestone payment to Ablynx from Boehringer under a 2007 deal to use...
BC Innovations | May 21, 2015
Distillery Therapeutics

Therapeutics: Interleukin-1 (IL-1) β; IL-1 receptor; purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

Ophthalmic disease INDICATION: Age-related macular degeneration (AMD) In vitro and mouse studies suggest inhibiting P2RX7 or IL-1β/IL-1 receptor signaling could help treat AMD. Subretinal accumulation of chemokine CX3C motif receptor 1 ( CX3CR1 )-deficient mononuclear cells...
BC Innovations | May 22, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Chemokine CX3C motif receptor 1 (CX3CR1); chemokine CX3C motif ligand 1 (CX3CL1; fractalkine) In vitro and mouse studies suggest antagonizing CX3CR1 or preventing cleavage...
BC Innovations | Oct 24, 2013
Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Chemokine CX3C motif receptor 1 (CX3CR1) promoter-dependent gene expression in microglia A microglia-specific expression system could help study the role of...
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Glomerulonephritis Chemokine CX3C motif receptor 1 (CX3CR1) Mouse studies suggest inhibiting CX3CR1 could help treat glomerulonephritis. In a mouse model of crescentic glomerulonephritis, Cx3cr1...
BC Innovations | May 2, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); chemokine CX3C motif receptor 1 (CX3CR1) In vitro and mouse studies suggest...
BC Innovations | Jul 21, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Chemokine CX3C motif receptor 1 (CX3CR1) Mouse studies suggest inhibiting CX3CR1 could help treat SCI. In a mouse model of SCI,...
Items per page:
1 - 10 of 15